Related Experiment Video
Updated: Sep 2, 2026
The Monoiodoacetate Model of Osteoarthritis Pain in the Mouse
Published on: May 16, 2016
Arachnoiditis from myelography with iopamidol, metrizamide, and iocarmate compared in the animal model
Abstract:
A new aqueous myelographic contrast media, iopamidol, was compared to iocarmate and metrizamide with respect to the risk of arachnoiditis. Macaque monkeys underwent myelography with one of the three contrast media. Twelve weeks later, the animals were restudied with myelography, then sacrificed for histologic studies of the arachnoid. Results suggest that iopamidol is safer than iocarmate and equivalent to metrizamide with respect to the risk of arachnoiditis.
Insights
New myelographic contrast media, iopamidol, was evaluated for arachnoiditis risk. Results indicate iopamidol is safer than iocarmate and comparable to metrizamide, suggesting improved safety for spinal imaging procedures.
Area of Science:
- Radiology and Imaging
- Neuroscience
- Medical Research
Background:
- Myelography requires contrast media for spinal imaging.
- Certain contrast agents carry risks, including arachnoiditis.
- Evaluating the safety profile of new contrast agents is crucial.
Purpose of the Study:
- To compare the risk of arachnoiditis associated with a new aqueous myelographic contrast medium, iopamidol.
- To assess iopamidol's safety relative to established agents, iocarmate and metrizamide.
Main Methods:
- Macaque monkeys were subjected to myelography using iopamidol, iocarmate, or metrizamide.
- Animals were re-evaluated with myelography after 12 weeks.
- Histologic examination of the arachnoid was performed for arachnoiditis assessment.
Main Results:
- Iopamidol demonstrated a lower risk of arachnoiditis compared to iocarmate.
- The risk of arachnoiditis with iopamidol was found to be equivalent to that of metrizamide.
- Histologic findings supported the comparative safety of iopamidol.
Conclusions:
- Iopamidol appears to be a safer alternative to iocarmate for myelography regarding arachnoiditis risk.
- Iopamidol offers a safety profile comparable to metrizamide for spinal contrast imaging.
- These findings support the potential use of iopamidol in clinical myelography.
